Реланиум

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Реланиум

Property Description
Active ingredient Diazepam
Form Tablets, Injection Solution, Rectal Solution
Pharmacological class Benzodiazepine derivative, CNS Depressant
Common use Anxiolytic, Anticonvulsant, Muscle Relaxant
Origin Synthetic Compound

Реланиум is a long-established trade name, originating in Europe, for a medicinal preparation whose active ingredient is Diazepam, chemically defined as a benzodiazepine derivative and a potent Central Nervous System (CNS) depressant. This compound is a synthetically produced substance, with its effectiveness in calming the nervous system supported by extensive pharmacological studies. Diazepam is unique within its class for having a relatively long-acting profile, resulting in a sustained therapeutic effect, a feature that distinguishes it from several shorter-acting benzodiazepine analogues. This core identity as a CNS depressant establishes it as a highly recognized psychotropic substance used to manage conditions related to nervous system hyperexcitability.

Composition, Forms, and General Therapeutic Roles

The composition of Реланиум is centered on its single active ingredient, Diazepam (International Nonproprietary Name, INN), formulated as a single-component product. The medication is made available across diverse dosage forms, including standard tablets for oral administration, a sterile solution for injection in ampoules for rapid parenteral use, and a specialized rectal solution (enema), allowing for versatile routes of administration, particularly in acute care settings. Diazepam is clinically recognized for its ability to function as a powerful skeletal muscle relaxant and anticonvulsant in situations where rapid nerve impulse reduction is necessary. Its broad therapeutic utility means its action as a tranquilizer and anxiolytic provides general stability and relief from severe nervous tension.

Regulatory References

  1. MedlinePlus
  2. NCBI Bookshelf (NIH)

What side effects are possible with Реланиум?

Possible side effects and safety information

The safety profile of Реланиум (Diazepam) is defined by its action as a Central Nervous System (CNS) depressant. Officially documented adverse reactions are categorized by frequency and the physiological systems affected, based on regulatory labeling.


Adverse Reaction Classification

Classification Common Reactions (CNS & Musculoskeletal)
Common Drowsiness, fatigue, muscle weakness, and ataxia (unsteadiness). These effects are frequently observed at the beginning of treatment.
Less Frequently Reported Confusion, headache, slurred speech (dysarthria), changes in libido, nausea, constipation, urinary retention, and visual disturbances like blurred vision.

Serious Adverse Reactions and Safety Constraints

The prescribing information highlights the risk of Serious Adverse Reactions. These include profound respiratory depression, coma, and death, particularly when used concurrently with opioid medications or alcohol, a risk explicitly warned against in regulatory documents. Continued or prolonged use carries the documented risk of developing physical and psychological dependence, leading to a severe Acute Withdrawal Syndrome upon abrupt cessation.

Safety constraints and formal contraindications are specified for certain patient populations and conditions. This medication should not be used in individuals with pre-existing conditions such as severe hepatic impairment, severe respiratory insufficiency, Myasthenia Gravis, or acute narrow-angle glaucoma. Furthermore, older adults are noted as being more sensitive to the CNS depressant effects, necessitating caution.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for Реланиум (Diazepam) overdose focuses strictly on documented clinical manifestations and mandated emergency actions. Overdose presentation typically reflects Central Nervous System (CNS) Depression, with symptoms ranging from somnolence, lethargy, confusion, and ataxia (lack of coordination) to severe outcomes.

Documented Overdose Outcomes

Severe and potentially life-threatening outcomes documented in regulatory labeling include respiratory depression, significant hypotension (low blood pressure), and coma. These severe manifestations are particularly noted in cases of massive ingestion or co-ingestion with other CNS depressants, such as alcohol.

Required Emergency Actions

Immediate medical attention is required for any suspected overdose. The official guidance strictly mandates contacting emergency services immediately if severe symptoms like breathing difficulty, unresponsiveness, or profound CNS depression occur. Management is primarily symptomatic and supportive, focusing on securing a patent airway and monitoring vital signs. Due to the long half-life of Diazepam, regulatory bodies emphasize the need for prolonged observation and monitoring in a hospital setting. While a specific antagonist, Flumazenil, is described in regulatory documents for reversal, its use is contingent upon strict medical supervision.

Therapeutic Uses of Реланиум

What Реланиум Treats: Main Uses and Benefits

Реланиум (Diazepam) is commonly used to help manage symptoms related to heightened neurological and muscular activity, providing supportive symptomatic relief across multiple clinical domains. The medication is applied in clinical settings that involve acute or unstable symptom patterns where short-term symptomatic assistance is needed to ease the overall symptom load. The medication is considered relevant across domains where additional symptomatic support is needed.

The medication is generally applied in addressing symptom clusters related to severe anxiety, acute convulsive seizures, and painful involuntary muscle spasms. It is also considered relevant for easing symptoms during acute alcohol withdrawal syndrome. In these scenarios, the primary benefit is offering symptomatic relief that helps patients cope more steadily with difficult episodes and contributes to maintaining a sense of stability.

“The supportive relief provided may assist patients with maintaining functional stability during phases when symptoms become temporarily overwhelming.”

Therapeutic Domains

Managing Acute Distress and Neurological Symptoms

This therapeutic domain is relevant for easing severe anxiety and nervous tension as well as being applied in addressing recurrent convulsive symptom patterns like status epilepticus. Furthermore, the medication is applied in managing the physical manifestations of acute alcohol withdrawal, including tremor and excitation. This approach helps address groups of symptoms that may appear suddenly or fluctuate, leading to noticeable functional strain.


Quick Fact: Relief for Painful Muscle Spasms The medication is relevant for easing symptoms related to involuntary muscle cramping, rigidity, and stiffness associated with conditions that produce increased muscular activity.

Regulatory References

  1. NIH MedlinePlus overview of Diazepam

Eligibility and Restrictions for Use

Who can and cannot use Реланиум?

Eligibility to use Реланиум (Diazepam) is strictly determined by official regulatory documents based on patient health status and age. The medication is absolutely contraindicated in several populations due to the high risk of serious complications.

Absolute Non-Eligibility (Contraindications)

Individuals who must not use this medicine include patients diagnosed with Myasthenia Gravis, severe respiratory insufficiency, sleep apnea syndrome, severe hepatic insufficiency, or acute narrow-angle glaucoma. Use is also contraindicated in patients with a known hypersensitivity to diazepam or any component of the formulation.

Population Restrictions and Conditional Use

Population Group Regulatory Status
Pediatric Patients Contraindicated under 6 months of age (oral forms).
Older Adults (Geriatric) Use requires extreme care and mandatory lower initial doses.
Pregnancy/Lactation Restricted; use during pregnancy is considered only when necessary, and caution is required during breastfeeding.
Organ Impairment Severe Hepatic Impairment is contraindicated; mild to moderate requires caution.

Use requires extreme caution in patients with a history of alcohol or drug use disorder or in those with chronic pulmonary insufficiency.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for this drug (Diazepam) focuses on interactions that modify its systemic exposure or increase the risk of central nervous system (CNS) depression.

Interaction Scope

Category Regulatory Basis for Interaction
Interacting Categories Opioid analgesics, alcohol, barbiturates, and other CNS depressants.
Mechanistic Basis Pharmacodynamic (PD) enhancement of CNS depression; Pharmacokinetic (PK) inhibition of CYP3A4 and CYP2C19 enzymes
Exposure Modifiers Inhibitors of CYP3A4 and CYP2C19 (e.g., cimetidine, fluvoxamine, ketoconazole) increase drug levels.
Timing Constraints Administration with a moderate fat meal delays and decreases absorption.
Related Restriction Simultaneous ingestion of alcohol is strongly restricted due to risk of profound sedation and respiratory depression.

Official Interaction Statements

  • Concomitant use with opioid analgesics is associated with a serious risk of profound sedation, respiratory depression, coma, and death due to additive depressant effects.
  • Co-administration with alcohol and other CNS depressants increases the risk of enhanced sedation and potential respiratory complications.
  • Drugs that inhibit the metabolizing enzymes CYP3A4 and CYP2C19 can elevate plasma concentrations, potentially leading to increased and prolonged clinical effects.
  • The drug's absorption is delayed when administered with food.

Connection to the Overall Interaction Profile

Regulatory documents structure the interaction profile by identifying substances that lead to additive CNS effects (PD risk) and those that inhibit metabolism (PK risk). This mandates constraints on co-administration, requiring avoidance or close monitoring to mitigate the risk of severely altered systemic exposure or respiratory complications.

Mechanism of Action

The active ingredient, Diazepam, achieves its physiological effects by enhancing the function of the central nervous system's main inhibitory system, the GABAergic pathway. The core mechanism involves acting as a Positive Allosteric Modulator (PAM) at the GABA A receptor complex, which is a chloride ion channel.

Diazepam binds to a specific site on the receptor, inducing a conformational change that increases the efficiency of the endogenous neurotransmitter, GABA. This leads to a more frequent opening of the chloride channel, amplifying the influx of negatively charged chloride ions ( Cl^-). The cellular consequence is neuronal hyperpolarization, a state where the nerve cell membrane potential stabilizes, making the neuron less capable of generating or propagating an action potential. This cascade results in widespread neuronal depression.

Specific action on GABA A subunits, particularly in the limbic system and spinal cord motor pathways, leads to the functional depression of these neural circuits. This mechanism causes suppression of motor reflex excitability and the stabilization of neuronal membranes against rapid depolarization. The allosteric modulation is strictly conditional; it relies on the presence of GABA and is subject to functional adaptation (tolerance) upon chronic exposure.

Dosage and Administration Information

The administration of Diazepam (Реланиум) is structured to address both routine and acute clinical needs through various routes. The medication is available as oral tablets for routine management, and as a solution for injection (Intravenous and Intramuscular) and rectal preparations for rapid, acute intervention.

Oral dosing for adults typically starts and maintains within the 2 mg to 10 mg range per dose, usually administered in divided doses 2 to 4 times daily. Tablets may be taken with or without food. For older adults and patients with hepatic impairment, guidelines suggest beginning with the lowest effective dose, often half the standard adult dose, and gradually increasing only as necessary.

For urgent needs, such as acute convulsive states, the intravenous dose is administered slowly, at a rate not exceeding 5 mg per minute, and the injection solution must not be mixed with other solutions in the syringe to prevent precipitation. Importantly, the duration of therapy for anxiety and related conditions should be kept as short as possible, generally not exceeding 2 to 4 weeks of continuous use. Upon planned discontinuation, the dosage must be gradually reduced (tapered) to prevent withdrawal phenomena. The medicine is not recommended for use in infants under six months of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Реланиум (Diazepam)

Evidence for Use in Acute Convulsive Seizures

Реланиум (Diazepam) was studied for use during acute convulsive events, which are considered conditions associated with acute or disruptive episodes. Research for this condition includes controlled Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies included populations of adults and children across a wide age range who had been observed with seizure episodes, often in acute care settings.

The research examined outcomes describing episodic or acute changes, specifically monitoring the metrics related to seizure termination and the time elapsed to measured changes. Findings describe patterns of measured change that were observed during the study period. Long-term effects are not fully established after the acute event, as research is concentrated entirely on the immediate resolution of the seizure.


Evidence for Short-Term Relief of Severe Anxiety and Nervous Tension

Реланиум was evaluated in studies for conditions involving periods of heightened symptoms of severe anxiety and nervous tension. Research exploring this condition involved short-term, placebo-controlled RCTs and trials comparing the medication to other anxiolytics.

The research explored short-term symptom changes, focusing on outcomes monitoring physiological strain or stress and patient-reported outcomes describing perceived discomfort. Findings indicate patterns of measured change in anxiety symptoms when compared to non-active treatments.

Research highlights a potential for tolerance, which has been observed to be associated with the duration of continuous use in some studies. Data for certain groups remain insufficient, and certainty remains low when attempting to generalize findings to longer periods of continuous use.


Research Gaps and Uncertainty About Реланиум

While the medication was studied for a variety of conditions, comparative evidence is lacking in some areas, particularly large-scale trials comparing it against non-pharmacological therapies for muscle spasms. The evidence quality varies across studies, particularly between very old foundational trials and modern comparative research.

Uncertainty remains regarding the optimal dosing strategies for managing acute alcohol withdrawal, despite the existing clinical guidance that includes the drug in managing this condition.

Key Studies & References

  1. Diazepam Oral Tablet: MedlinePlus Drug Information
  2. Diazepam: StatPearls [Internet] (Covers pharmacology, all indications, and limitations)

Frequently Asked Questions (FAQ)

Common questions about Реланиум (FAQ)

Q: How quickly does Реланиум start working?

The onset of effect depends on the form used. Following an intravenous injection in acute settings, the effects are rapid, typically starting within 1 to 5 minutes.

When taken in oral form, official product information indicates the effects may generally start within 30 minutes to one hour after administration.


Q: How long do the effects of Реланиум typically last?

As a long-acting medicine, its effects on the body are sustained. The initial therapeutic and sedative effects of a single dose generally last between 4 and 6 hours.

However, due to its long-acting nature, the full sedative effects may continue for several hours afterward.


Q: Is it true that Реланиум can cause dependence?

Yes, regulatory documents state that continued use of this drug, even as prescribed, may lead to the development of physical and psychological dependence. Abrupt discontinuation or rapid dosage reduction may precipitate severe acute withdrawal reactions.

Official product information indicates that the dosage must be gradually reduced (tapered) when stopping treatment.


Q: Can Реланиум be taken during pregnancy?

Use during pregnancy is generally restricted and is considered only if a doctor determines that the potential benefit is greater than the potential risk to the fetus.

Official information advises that if the medicine is used late in pregnancy (third trimester), the newborn should be monitored for potential withdrawal syndrome symptoms.


Q: Can older adults use Реланиум safely?

Official labeling indicates that older and very ill patients are more sensitive to the central nervous system depressant effects of the medicine. Due to this increased sensitivity, these patient populations are typically started on the lowest possible effective dose, according to official guidance.

Caution is required because long-acting benzodiazepines are often not recommended for this group due to risks like falls and delayed metabolism.


Q: What is the difference between Реланиум and Xanax (Alprazolam)?

The primary difference between Реланиум (Diazepam) and Alprazolam (Xanax) is related to their duration of action. Реланиум is classified as a long-acting benzodiazepine with a sustained effect.

In contrast, Alprazolam is classified as a shorter-acting benzodiazepine.


Q: Is there a maximum amount of time Реланиум should be used?

For conditions like anxiety, regulatory guidelines generally recommend keeping the duration of continuous therapy as short as possible. The duration often does not exceed 2 to 4 weeks due to the risk of tolerance and dependence.

The efficacy of continuous use beyond four months has not been established in research.


Q: Does taking Реланиум with grapefruit juice cause a problem?

Grapefruit and grapefruit juice may cause an interaction with this medicine. Regulatory documentation highlights that this fruit may affect the enzymes in the body (CYP3A4) that break down the drug.

This effect can potentially lead to increased drug levels in the blood and a higher risk of side effects.


Q: What should I do if I miss a dose of Реланиум?

Regulatory guidelines do not specify missed dose instructions. If a dose is missed, individuals should consult with a healthcare professional, such as a doctor or pharmacist, for guidance.

Consulting a professional is necessary to determine the appropriate course of action, which may involve guidance on taking the missed dose or adjusting the schedule.


Q: Can Реланиум be taken by someone with liver or kidney problems?

Official sources indicate that the medicine is absolutely contraindicated in individuals with severe liver insufficiency (failure).

For patients with milder liver impairment or with kidney problems, official guidance requires caution, and a lower starting dosage is specified in regulatory information for these conditions.


Q: How is Реланиум different from other benzodiazepines?

Реланиум is distinct as a long-acting benzodiazepine known for its wide therapeutic range. It is primarily recognized for its strong effects as a skeletal muscle relaxant and anticonvulsant, in addition to its use as an anxiolytic.

Other benzodiazepines may be classified as shorter-acting or have primary indications focused more narrowly on specific acute uses or insomnia.


Q: Does Реланиум show up on standard drug tests?

The active ingredient (Diazepam) and its major metabolite (Nordiazepam) are substances that are specifically tested for in standard drug screens for benzodiazepines.

The actual detection window can vary widely based on the drug test type, the dosage used, the frequency of use, and individual metabolic rates.


Q: Does Реланиум interact with herbal supplements like St. John's Wort?

Regulatory warnings include certain herbal supplements, particularly those with sedative properties used for anxiety or sleep, such as valerian or passionflower.

Combining these with the medicine may increase the sedative effects. Official guidance indicates that other herbal products may also affect how the body processes the drug, necessitating caution.


Q: Can Реланиум affect my mood or cause changes in behavior?

Official labeling notes the possibility of paradoxical reactions, which are unusual, opposite effects. These may include acute hyperexcited states, anxiety, hallucinations, increased irritability, or aggression.

If these specific mood or behavior changes occur, official labeling indicates that the use of the drug should be discontinued or reviewed.


Q: Does Реланиум interact with common over-the-counter medications?

The medicine can interact with certain common over-the-counter (OTC) products. Specifically, products that cause drowsiness or contain sedating antihistamines (like diphenhydramine) can increase the risk of excessive sleepiness and slowed breathing when combined with this medicine.


Q: Is there a link between Реланиум and birth defects?

Official information indicates that older studies suggested a potential, small increase in the risk of certain birth defects, such as oral clefts, with first-trimester use.

However, recent, larger studies have generally not found a clear, significant increase in the overall chance of birth defects above the background population risk.


Q: What medical conditions prevent a person from using Реланиум?

Official sources list several absolute contraindications where the drug must not be used. These conditions include: severe hepatic insufficiency (liver failure), severe respiratory insufficiency, Myasthenia Gravis (a muscle weakness disorder), sleep apnea syndrome, and acute narrow-angle glaucoma.

How should Реланиум be stored and disposed of?

Official Storage and Disposal Requirements

Реланиум (diazepam) must be stored and disposed of according to official regulatory specifications to maintain its stability and security.

Requirement Type Official Condition
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep in the original, tightly closed container; protect from light and moisture.
Security The medication must be kept out of the sight and reach of children and stored in a safe, locked location.
Disposal Dispose of unused or expired product using a DEA-authorized drug take-back program. If a program is unavailable, mix with an unappealing substance, place in a sealed container, and discard in household trash; do not flush.

These conditions are set by regulatory bodies to ensure product quality and prevent the medication from being misused or improperly handled.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Реланиум found in:

A-Z Index: